Regulatory Strategy & Insight
Clear regulatory direction shapes timelines and protects programme value. For investors, it is also one of the clearest signals that a programme is being managed well. Strategy & Insight at PrimeRA covers regulatory pathway evaluation, investment due diligence, designation strategy, platform innovation and the advisory structures that allow organisations to build a defensible position before substantive agency engagement begins. It operates independently from our delivery pillar - and informs everything that follows.
Strategic clarity built on hands-on programme experience
At PrimeRA, we draw on decades of direct experience developing, submitting and defending advanced therapy products to translate complex regulatory questions into clear, actionable positions. Our recommendations draw on what the agencies have said, the precedents that exist, and what the programme's data and timeline can credibly support.
The scope ranges from evaluating the most efficient development pathway for a novel product to providing investors with an independent read of a programme's regulatory standing. Designation strategy is a core component: identifying which designations to pursue, when to apply, and how to extract maximum benefit from each. Where broader expert input is needed, PrimeRA can form and coordinate a Regulatory Advisory Board, selecting consultants with the specific modality or discipline expertise the programme requires. And for programmes that need a structured planning tool, PrimeRA prepares a bespoke regulatory roadmap: a working document that places every regulatory milestone in the context of data generation and approval timelines.
Identifying the most efficient path from data to approval
PrimeRA evaluates all available regulatory pathways - established and emerging - to determine which development strategy best serves the programme's science, timeline and commercial objectives. Where a global development strategy is the goal, PrimeRA advises on combined EU/US approaches that protect the programme across both jurisdictions from the outset, avoiding the costly course-corrections that arise when jurisdictions are addressed sequentially. For ATMPs and other products at the frontier of regulatory science, this also requires familiarity with how agencies are evolving their frameworks in real time: platform approaches, pilot schemes, novel designation criteria and procedural innovations that may not yet be widely understood or fully utilised.
Designation strategy is a core component of this work. Orphan, PRIME, ILAP (MHRA), Fast Track, Breakthrough, RMAT and RPDD (FDA) each carry specific procedural and commercial benefits - but their value depends on timing and sequencing. PrimeRA advises on which designations are appropriate, when to apply, and how to make best use of the associated benefits: early scientific advice, rolling review, fee waivers and priority review. The output that makes this actionable is a bespoke regulatory roadmap: a working planning document placing every regulatory milestone in the context of data generation timelines and the decisions that depend on them.
An independent regulatory read for investors and acquirers
Regulatory risk is one of the most frequently misread variables in ATMP investment decisions. PrimeRA supports investors, acquirers and technology transfer offices with independent regulatory due diligence, drawing on direct experience translating cutting-edge cell and gene therapy science into approved medicinal products. The assessment goes beyond a review of existing documents: it evaluates the credibility of the regulatory strategy, the quality and completeness of the dossier to date, the appropriateness of the chosen pathway, and the likely trajectory through to approval.
For academic or institutional programmes transitioning into commercial development - where the regulatory infrastructure is often nascent or absent - PrimeRA provides practical input on what a commercially viable regulatory strategy requires from the outset, and what must be in place before meaningful agency engagement can begin. This includes assessment of the data package, the product characterisation position and the foundational decisions that will shape the development trajectory.
Strategy built on the programmes that set the precedents
PrimeRA's partners have worked on leading ATMP products such as: the first gene therapy approved in Europe (AAV), the first CAR-T for CD19-directed malignancies submitted for approval in Europe, the first CAR-T cell therapy submitted for approval in the US, and the first CRISPR gene editing product approved globally. The strategic positions PrimeRA takes are built on direct experience of the regulatory decisions that established these precedents.
PrimeRA has presented on platform approaches and novel regulatory frameworks at the EMA Quality Innovation Group (November 2024) and the MEB Science Day (2025), and has applied emerging pathways in client programmes. Understanding of how agency frameworks are evolving is embedded in every engagement.
PrimeRA's strategy and delivery functions sit within the same organisation. When the team advising on the pathway is the same team executing it, the strategy stays anchored in what is achievable. Unrealistic positions are identified before they become costly commitments, and the move from plan to action is immediate. For clients managing investor pressure and tight development timelines, this integration is a meaningful protection.
Advice and insight - before and alongside delivery
Strategy & Insight covers the analysis, planning and advisory work that determines how a regulatory programme is structured — from initial pathway selection through to the designation and agency engagement strategy that shapes the development trajectory. Hands-on execution of the resulting submissions and procedures is delivered under the Delivery pillar.